← Leaderboards
Michael A Pulsipher
University Of Pittsburgh At Pittsburgh
$13,522,310
Attributed
$25,052,625
Total exposure
14
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,052,625 · 14
By mechanism
U01$11,015,224 · 3
R01$9,031,751 · 4
UH3$2,102,265 · 1
U10$839,000 · 1
R34$796,405 · 1
UG3$692,343 · 1
Top collaborators
- Galen E Switzer12 shared
- David A Williams7 shared
- Leslie S Kean5 shared
- Sung-Yun Pai4 shared
- Jeffery J Auletta3 shared
- Alan S. Wayne3 shared
- Kevin S Baker1 shared
- Eneida R Nemecek1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Madhavi K Ganapathiraju$1,921,445
- Galen E Switzer$10,522,784
Others in their field
Top investigators on “Childhood”
- Gregory H Reaman · National Childhood Cancer Foundation$268,060,146
- Barbara Driver · Westat, Inc.$206,410,885
- Sharon A Nachman · Johns Hopkins University$191,166,598
- Peter C Adamson · National Childhood Cancer Foundation$190,988,407
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$187,267,729
- James E. Gern · University Of Wisconsin-Madison$149,875,125
Research focus
ChildhoodTransplantationBloodChildHematopoietic Stem CellsDoseSiblingsCohortStem CellsHematopoietic Stem Cell TransplantationFludarabineNorth AmericaSafetyResponseSourceImmuneToxic EffectFundingRandomizedRegimenAffectAdultAllogenicHigh Risk
Grant awards (48)
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage$1,076,893
U01 · FY2025 · AI
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia$704,815
UH3 · FY2025 · HL
Donor health-related quality-of-life and physician decision-making in the context of haploidentical hematopoietic stem cell transplantation (HaploQOL)$581,857
R01 · FY2025 · HL
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage$1
U01 · FY2025 · AI
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage$1,072,951
U01 · FY2024 · AI
Donor health-related quality-of-life and physician decision-making in the context of haploidentical hematopoietic stem cell transplantation (HaploQOL)$710,059
R01 · FY2024 · HL
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia$692,607
UH3 · FY2024 · HL
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$989,251
U01 · FY2023 · AI
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia$704,843
UH3 · FY2023 · HL
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$995,166
U01 · FY2022 · AI
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia$692,343
UG3 · FY2022 · HL
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors$673,216
R01 · FY2022 · HL
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors$709,988
R01 · FY2021 · HL
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$526,140
U01 · FY2021 · AI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$18,548
U01 · FY2021 · AI · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$1,465,945
U01 · FY2020 · AI · contact PI
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors$711,439
R01 · FY2020 · HL
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$18,548
U01 · FY2020 · AI · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$1,542,032
U01 · FY2019 · AI · contact PI
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors$725,340
R01 · FY2019 · HL
KIR-FAVORABLE HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN$283,072
R01 · FY2019 · CA · contact PI
Feasibility study randomizing IST vs URD BMT for children with aplastic anemia$258,981
R34 · FY2019 · HL
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant Consortium$191,673
UG1 · FY2019 · HL · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$1,496,446
U01 · FY2018 · AI · contact PI
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors$784,925
R01 · FY2018 · HL
KIR-FAVORABLE HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN$291,828
R01 · FY2018 · CA · contact PI
Feasibility study randomizing IST vs URD BMT for children with aplastic anemia$259,035
R34 · FY2018 · HL
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant Consortium$185,896
UG1 · FY2018 · HL · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$1,417,336
U01 · FY2017 · AI · contact PI
Feasibility study randomizing IST vs URD BMT for children with aplastic anemia$278,389
R34 · FY2017 · HL
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant Consortium$180,568
UG1 · FY2017 · HL · contact PI
KIR-FAVORABLE HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN$90,772
R01 · FY2017 · CA · contact PI
KIR-FAVORABLE HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN$370,071
R01 · FY2016 · CA · contact PI
Blood and Marrow Transplant Clinical Trials Network$172,328
U10 · FY2016 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network$172,328
U10 · FY2015 · HL · contact PI
PBMTC-ASPHO 2014: NEW FRONTIERS IN PEDIATRIC STEM CELL TRANSPLANTATION$5,000
R13 · FY2015 · HL
Blood and Marrow Transplant Clinical Trials Network$117,888
U10 · FY2014 · HL · contact PI
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life$571,161
R01 · FY2013 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network$117,888
U10 · FY2013 · HL · contact PI
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life$598,019
R01 · FY2012 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network$130,410
U10 · FY2012 · HL · contact PI
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life$606,068
R01 · FY2011 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network$128,158
U10 · FY2011 · HL · contact PI
Late Effects after Pediatric HSCT: State of the Science, Future Directions$12,500
R13 · FY2011 · CA · contact PI
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life$622,542
R01 · FY2010 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network$201,530
U01 · FY2010 · HL · contact PI
RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life$701,394
R01 · FY2009 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network$194,437
U01 · FY2009 · HL · contact PI